A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis ...

A group at Niigata University succeeded in the early diagnosis of leptomeningeal disease in H3K27M-mutant diffuse midline ...

Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas by Detection of H3F3A K27M Mutation in Circulating Tumor DNA ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of ...

In connection with the SEPA executed in December 2023 and amended in January 2024, Calidi was granted the option to sell up to $25 million of common stock over a three-year period, subject to certain ...

IGFBP2表达评估idh突变的胶质瘤患者生存 （IGFBP2 expression predicts IDH-mutant glioma patient survival） ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, reported a ca ...

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of ...

Treatment options for patients with glioblastoma multiforme (GBM), the most common form of malignant gliomas, now include anti-angiogenic therapy after failure of standard multi-modality treatments.

These tumors are less likely to spread to surrounding tissues, compared with higher-grade tumors, so they often have better outcomes. Low-grade gliomas are tumors that start in the glial cells in ...

Hormone replacement therapy to ease menopause symptoms doesn’t increase a woman’s risk of brain tumors.Researchers fo ...